Drug Profile
Research programme: immune tolerance technology - BioMarin Pharmaceutical
Latest Information Update: 10 Mar 2010
Price :
$50
*
At a glance
- Originator BioMarin Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 07 Jul 2006 Preclinical trials in Autoimmune disorders in USA (unspecified route)